Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy

Epilepsy Research

Volumn 69, Issue 2, 2006, Pages 170-176

  Striano, Salvatore ^a   Striano, Pasquale ^a   Di Nocera, Pierpaolo ^b   Italiano, Domenico ^c   Fasiello, Cecilia ^b   Ruosi, Patrizia ^a   Bilo, Leonilda ^a   Pisani, Francesco ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ASL 1   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Adverse effects; Monohydroxycarbazepine; Oxcarbazepine; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; DIBENZAZEPINE DERIVATIVE; DRUG METABOLITE; ETIRACETAM; GABAPENTIN; HYDROXYCARBAZEPINE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN;

ADULT; ARTICLE; ATAXIA; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG MONITORING; EPILEPSY; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPONATREMIA; MALE; NAUSEA; NYSTAGMUS; OBSERVATION; OUTPATIENT DEPARTMENT; PATIENT MONITORING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SAMPLING; SEDATION; SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 33646162435     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2006.01.011     Document Type: Article

References (17)

1. Bang L.M., and Goa K.L. Spotlight on oxcarbazepine in epilepsy. CNS Drugs 18 (2004) 57-61
2. Barcs G., Walker E.B., Elger C.E., et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41 (2000) 1597-1607
3. Benes J., Parada A., Figuereido A., et al. Anticonvulsant and sodium channel- blocking properties of novel 10, 11-dihydro-5H-dibenz [b,f] azepine-5-carboxamide derivatives. J. Med. Chem. 42 (1999) 2582-2587
4. Dong X., Leppik I.E., White J., and Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 65 (2005) 1976-1978
5. Edelbroek P.M., Augustijn P.B., de Haan G.J., Rademaker M.V., and Geesink H.H. Change in oxcarbazepine (Trileptal) formulation is associated with more side effects and higher blood concentrations. J. Neurol. Neurosurg. Psychiatr. 71 (2001) 708-709
6. Froescher W., Kraemer G., Schmidt D., et al. Serum concentrations of anticonvulsants: practical guidelines for measuring and useful interpretation. Therapy Committee of the German Section of the International Epilepsy League. Nervenartz 70 (1999) 172-177 (in German)
7. Johannessen S.I., Battino D., Berry D.J., et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 25 (2003) 347-363
8. Levert H., Odou P., and Robert H.L.C. Determination of oxcarbazepine and its active metabolite in human serum. J. Pharm. Biomed. Anal. 28 (2002) 517-525
9. May T.W., Korn-Merker E., and Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin. Pharmacokinet. 42 (2003) 1023-1042
10. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants?. Clin. Pharmacokinet. 38 (2000) 191-204
11. Pierre A.B., Vigonius U., Pohlmann H., Guerreiro C.A.M., Kochen S., Saffer D., and Moore A. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epil. Res. 27 (1997) 195-204
12. Sallas W.M., Milosavljev S., D'souza J., and Hossain M. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin. Pharmacol. Ther. 74 (2003) 138-149
13. Tartara A., Galimberti C.A., Manni R., et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br. J. Clin. Pharmacol. 36 (1993) 366-368
14. Tomson T., and Johannessen S.I. Therapeutic monitoring of the new antiepileptic drugs. Eur. J. Clin. Pharmacol. 55 (2000) 697-705
15. van Heiningen P.N.M., Eve M.D., Oosterhuis B., et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin. Pharmacol. Ther. 50 (1991) 410-419
16. van Parys J.A.P., Meijer J.W.A., and Segers J.P. Dose-concentration proportionality in epileptic patients stabilized on oxcarbazepine: effect of co-medication. Epilepsia 32 Suppl. 1 (1991) 70
17. Zweigh H.H., and Campbell G. Receiver operating characteristic (ROC) plots: a fundamental evolution tool in medicine. Clin. Chem. 39 (1993) 561-577